These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 16965871)

  • 1. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
    Macklis RM; Pohlman B
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
    Hendrix CS; de Leon C; Dillman RO
    Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
    Tomblyn M
    Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team.
    Macklis RM
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S4-6. PubMed ID: 16979439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A
    Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
    Clayton J
    Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions in radioimmunotherapy for B-cell lymphoma.
    Horning SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Gordon LI
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
    Cheson BD
    BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
    Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
    J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up.
    Martínez A; Martínez-Ramirez M; Martínez-Caballero D; Beneit P; Clavel J; Figueroa G; Verdú J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(1):13-19. PubMed ID: 27422155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.